Annexon Biosciences is a biopharmaceutical company focused on developing innovative therapies for individuals suffering from classical complement-mediated neuroinflammatory diseases affecting the body, brain, and eye. With a unique scientific approach that targets upstream C1q to inhibit the classical complement inflammatory cascade, Annexon is advancing a late-stage clinical platform aimed at providing significant benefits for various autoimmune, neurodegenerative, and ophthalmic conditions. The company has demonstrated proof-of-concept data in conditions such as Guillain-Barré syndrome, Huntington’s disease, and geographic atrophy, and is committed to expediting the development of new treatments. Headquartered in Brisbane, California, and publicly traded on Nasdaq under the ticker symbol ANNX, Annexon values diversity, equity, and inclusion in its workplace, encouraging exceptional talent from all backgrounds to join its mission of making a meaningful impact.